Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2025-12-11 00:00:00 ET · period of report 2025-12-09 · accession 0001226690-25-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-11 | 2025-12-09 | REGN | YANCOPOULOS GEORGE | Pres, CSO, Bd. Co-COB, Dir | M - OptEx | $555.67 | +146.8K | 442.3K | +50% | +$81.58M |
| D | 2025-12-11 | 2025-12-09 | REGN | YANCOPOULOS GEORGE | Pres, CSO, Bd. Co-COB, Dir | F - Tax | $701.51 | -131.9K | 310.5K | -30% | -$92.51M |
| D | 2025-12-11 | 2025-12-09 | REGN | YANCOPOULOS GEORGE | Pres, CSO, Bd. Co-COB, Dir | M - OptEx | $0.00 | -146.8K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-09 | M | A | 146,815 | $555.67 | 442,334 | D | — | — | |
| 2 | Common | Common Stock | 2025-12-09 | F | D | 131,874 | $701.51 | 310,460 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2025-12-09 | M | D | 146,815 | $0.00 | 0 | D | $555.67 · — to 2025-12-16 | 146,815 Common Stock | (F2) The stock option award vested in four equal annual installments, commencing one year after the date of grant. |